Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.

Nevertheless, there was an observed trend towards improved PFS in patients with positive PD-L1 expression (7 months for PD-L1 ≥ 1% versus 3 months for PD-L1 < 1%, p = 0.27), as shown in the additional file, Figure S3 A.

also in 199 other papers